A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics and Immunogenicity of a Single Dose of 9MW1911 Injection in Healthy Subjects
Latest Information Update: 13 Dec 2023
At a glance
- Drugs 9MW 1911 (Primary)
- Indications Asthma; Atopic dermatitis; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Mabwell (Shanghai) Bioscience
Most Recent Events
- 13 Mar 2023 Status changed from recruiting to completed.
- 27 Apr 2022 Status changed from not yet recruiting to recruiting.
- 04 Jan 2022 New trial record